CURIS INC (CRIS)
About CURIS INC
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $9.4M
- Net income
- -$7.6M
- Total assets
- $20.0M
- Market cap
- $9.5M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $9.5M
- Shares outstanding
- 24.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 1, 2000
Curis Inc (CRIS) Stock Price
- Reported a net loss of $7.6M in FY2025.
- Trading 99% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CURIS INC.
Write a review
News about CURIS INC
News & sentiment via Polygon.io
Curis Inc: frequently asked questions
Is Curis Inc an American company?
Curis Inc is a US-based company headquartered in Lexington, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Curis Inc headquartered?
Curis Inc is headquartered in Lexington, Massachusetts, United States.
Is Curis Inc publicly traded?
Yes — Curis Inc is a publicly traded company. Its stock trades under the ticker symbol CRIS on the NASDAQ.
What does Curis Inc do?
Curis Inc is an American Pharmaceuticals company in the Health & Beauty sector.
